Chemoproteomic identification of a DPP4 homolog in Bacteroides thetaiotaomicron.


Journal

Nature chemical biology
ISSN: 1552-4469
Titre abrégé: Nat Chem Biol
Pays: United States
ID NLM: 101231976

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 01 08 2022
accepted: 08 05 2023
medline: 27 11 2023
pubmed: 23 6 2023
entrez: 22 6 2023
Statut: ppublish

Résumé

Serine hydrolases have important roles in signaling and human metabolism, yet little is known about their functions in gut commensal bacteria. Using bioinformatics and chemoproteomics, we identify serine hydrolases in the gut commensal Bacteroides thetaiotaomicron that are specific to the Bacteroidetes phylum. Two are predicted homologs of the human dipeptidyl peptidase 4 (hDPP4), a key enzyme that regulates insulin signaling. Our functional studies reveal that BT4193 is a true homolog of hDPP4 that can be inhibited by FDA-approved type 2 diabetes medications targeting hDPP4, while the other is a misannotated proline-specific triaminopeptidase. We demonstrate that BT4193 is important for envelope integrity and that loss of BT4193 reduces B. thetaiotaomicron fitness during in vitro growth within a diverse community. However, neither function is dependent on BT4193 proteolytic activity, suggesting a scaffolding or signaling function for this bacterial protease.

Identifiants

pubmed: 37349583
doi: 10.1038/s41589-023-01357-8
pii: 10.1038/s41589-023-01357-8
doi:

Substances chimiques

Dipeptidyl Peptidase 4 EC 3.4.14.5
Serine 452VLY9402

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1469-1479

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
pubmed: 29555994 pmcid: 6108420 doi: 10.1038/nature25979
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462–467 (2019).
pubmed: 31158845 pmcid: 6597290 doi: 10.1038/s41586-019-1291-3
Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).
pubmed: 21051639 pmcid: 3110694 doi: 10.1126/science.1191175
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, eaau6323 (2019).
pubmed: 31196984 doi: 10.1126/science.aau6323
Kidd, D., Liu, Y. & Cravatt, B. F. Profiling serine hydrolase activities in complex proteomes. Biochemistry 40, 4005–4015 (2001).
pubmed: 11300781 doi: 10.1021/bi002579j
Parasar, B. et al. Chemoproteomic profiling of gut microbiota-associated bile salt hydrolase activity. ACS Cent. Sci. 5, 867–873 (2019).
pubmed: 31139722 pmcid: 6535767 doi: 10.1021/acscentsci.9b00147
Wu, L. et al. Activity-based probes for functional interrogation of retaining β-glucuronidases. Nat. Chem. Biol. 13, 867–873 (2017).
pubmed: 28581485 doi: 10.1038/nchembio.2395
Whidbey, C. et al. A probe-enabled approach for the selective isolation and characterization of functionally active subpopulations in the gut microbiome. J. Am. Chem. Soc. 141, 42–47 (2019).
pubmed: 30541282 doi: 10.1021/jacs.8b09668
Chatterjee, S. et al. A comprehensive and scalable database search system for metaproteomics. BMC Genomics 17, 642 (2016).
pubmed: 27528457 pmcid: 4986259 doi: 10.1186/s12864-016-2855-3
Issa Isaac, N., Philippe, D., Nicholas, A., Raoult, D. & Eric, C. Metaproteomics of the human gut microbiota: challenges and contributions to other OMICS. Clin. Mass Spectrom. 14, 18–30 (2019).
pubmed: 34917758 doi: 10.1016/j.clinms.2019.06.001
Simon, G. M. & Cravatt, B. F. Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. J. Biol. Chem. 285, 11051–11055 (2010).
pubmed: 20147750 pmcid: 2856978 doi: 10.1074/jbc.R109.097600
Bachovchin, D. A. & Cravatt, B. F. The pharmacological landscape and therapeutic potential of serine hydrolases. Nat. Rev. Drug Discov. 11, 52–68 (2012).
pubmed: 22212679 pmcid: 3665514 doi: 10.1038/nrd3620
Ortega, C. et al. Systematic survey of serine hydrolase activity in Mycobacterium tuberculosis defines changes associated with persistence. Cell Chem. Biol. 23, 290–298 (2016).
pubmed: 26853625 pmcid: 4803444 doi: 10.1016/j.chembiol.2016.01.003
Babin, B. M. et al. Identification of covalent inhibitors that disrupt M. tuberculosis growth by targeting multiple serine hydrolases involved in lipid metabolism. Cell Chem. Biol. 29, 897–909 (2022).
pubmed: 34599874 doi: 10.1016/j.chembiol.2021.08.013
Li, M. et al. Identification of cell wall synthesis inhibitors active against Mycobacterium tuberculosis by competitive activity-based protein profiling. Cell Chem. Biol. 29, 883–896 (2022).
pubmed: 34599873 pmcid: 8964833 doi: 10.1016/j.chembiol.2021.09.002
Deacon, C. F. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front. Endocrinol. 10, 80 (2019).
doi: 10.3389/fendo.2019.00080
Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13, 7–18 (2011).
pubmed: 21114598 doi: 10.1111/j.1463-1326.2010.01306.x
Klemann, C., Wagner, L., Stephan, M. & von Hörsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin. Exp. Immunol. 185, 1–21 (2016).
pubmed: 26919392 pmcid: 4908298 doi: 10.1111/cei.12781
Sonnenburg, J. L. et al. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307, 1955–1959 (2005).
pubmed: 15790854 doi: 10.1126/science.1109051
Macfarlane, G. T., Allison, C., Gibson, S. A. W. & Cummings, J. H. Contribution of the microflora to proteolysis in the human large intestine. J. Appl. Bacteriol. 64, 37–46 (1988).
pubmed: 3127369 doi: 10.1111/j.1365-2672.1988.tb02427.x
Mills, R. H. et al. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat. Microbiol. 7, 262–276 (2022).
pubmed: 35087228 pmcid: 8852248 doi: 10.1038/s41564-021-01050-3
Bachovchin, D. A. et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc. Natl Acad. Sci. USA 107, 20941–20946 (2010).
pubmed: 21084632 pmcid: 3000285 doi: 10.1073/pnas.1011663107
Kaschani, F. et al. Diversity of serine hydrolase activities of unchallenged and Botrytis-infected Arabidopsis thaliana. Mol. Cell. Proteom. 8, 1082–1093 (2009).
doi: 10.1074/mcp.M800494-MCP200
Hatzios, S. K. et al. Chemoproteomic profiling of host and pathogen enzymes active in cholera. Nat. Chem. Biol. 12, 268–274 (2016).
pubmed: 26900865 pmcid: 4765928 doi: 10.1038/nchembio.2025
Lentz, C. S. et al. Identification of a S. aureus virulence factor by activity-based protein profiling (ABPP). Nat. Chem. Biol. 14, 609–617 (2018).
pubmed: 29769740 pmcid: 6202179 doi: 10.1038/s41589-018-0060-1
Keller, L. J. et al. Characterization of serine hydrolases across clinical isolates of commensal skin bacteria Staphylococcus epidermidis using activity-based protein profiling. ACS Infect. Dis. 6, 930–938 (2020).
pubmed: 32298574 doi: 10.1021/acsinfecdis.0c00095
Zweerink, S. et al. Activity-based protein profiling as a robust method for enzyme identification and screening in extremophilic Archaea. Nat. Commun. 8, 15352 (2017).
pubmed: 28480883 pmcid: 5424146 doi: 10.1038/ncomms15352
Human Microbiome Project Consortium. et al. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
doi: 10.1038/nature11234
Goodman, A. L. et al. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. Cell Host Microbe 6, 279–289 (2009).
pubmed: 19748469 pmcid: 2895552 doi: 10.1016/j.chom.2009.08.003
Rasmussen, H. B., Branner, S., Wiberg, F. C. & Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 10, 19–25 (2003).
pubmed: 12483204 doi: 10.1038/nsb882
Hino, M. et al. Glycylprolyl β-naphthylamidase activity in human serum. Clin. Chim. Acta 62, 5–11 (1975).
pubmed: 1149281 doi: 10.1016/0009-8981(75)90273-9
Macfarlane, S. & Macfarlane, G. T. Formation of a dipeptidyl arylamidase by Bacteroides splanchnicus NCTC 10825 with specificities towards glycylprolyl-x and valylalanine-x substrates. J. Med. Microbiol. 46, 547–555 (1997).
pubmed: 9236738 doi: 10.1099/00222615-46-7-547
Banbula, A. et al. Emerging family of proline-specific peptidases of Porphyromonas gingivalis: purification and characterization of serine dipeptidyl peptidase, a structural and functional homologue of mammalian prolyl dipeptidyl peptidase IV. Infect. Immun. 68, 1176–1182 (2000).
pubmed: 10678923 pmcid: 97264 doi: 10.1128/IAI.68.3.1176-1182.2000
Olivares, M. et al. The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia 61, 1838–1848 (2018).
pubmed: 29797022 pmcid: 6061172 doi: 10.1007/s00125-018-4647-6
Leiting, B. et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J. 371, 525–532 (2003).
pubmed: 12529175 pmcid: 1223300 doi: 10.1042/bj20021643
Cartmell, A. et al. A surface endogalactanase in Bacteroides thetaiotaomicron confers keystone status for arabinogalactan degradation. Nat. Microbiol. 3, 1314–1326 (2018).
pubmed: 30349080 pmcid: 6217937 doi: 10.1038/s41564-018-0258-8
Wilson, M. M., Anderson, D. E. & Bernstein, H. D. Analysis of the outer membrane proteome and secretome of Bacteroides fragilis reveals a multiplicity of secretion mechanisms. PLoS ONE 10, e0117732 (2015).
pubmed: 25658944 pmcid: 4319957 doi: 10.1371/journal.pone.0117732
Liu, H. et al. Functional genetics of human gut commensal Bacteroides thetaiotaomicron reveals metabolic requirements for growth across environments. Cell Rep. 34, 108789 (2021).
pubmed: 33657378 pmcid: 8121099 doi: 10.1016/j.celrep.2021.108789
Domingues, M. M. et al. Biophysical characterization of polymyxin b interaction with LPS aggregates and membrane model systems. Biopolymers 98, 338–344 (2012).
pubmed: 23193598 doi: 10.1002/bip.22095
Wang, L., Li, P., Tang, Z., Yan, X. & Feng, B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci. Rep. 6, 33251 (2016).
pubmed: 27633081 pmcid: 5025740 doi: 10.1038/srep33251
Aranda-Díaz, A. et al. Establishment and characterization of stable, diverse, fecal-derived in vitro microbial communities that model the intestinal microbiota. Cell Host Microbe 30, 260–272 (2022).
pubmed: 35051349 pmcid: 9082339 doi: 10.1016/j.chom.2021.12.008
Aranda-Díaz, A. et al. Assembly of gut-derived bacterial communities follows ‘early-bird’ resource utilization dynamics. Preprint at bioRxiv https://doi.org/10.1101/2023.01.13.523996 (2023).
Cullen, T. W. et al. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 347, 170–175 (2015).
pubmed: 25574022 pmcid: 4388331 doi: 10.1126/science.1260580
Miller, S. I. Antibiotic resistance and regulation of the Gram-negative bacterial outer membrane barrier by host innate immune molecules. mBio 7, e01541-16 (2016).
pubmed: 27677793 pmcid: 5040116 doi: 10.1128/mBio.01541-16
Sampson, B. A., Misra, R. & Benson, S. A. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 122, 491–501 (1989).
pubmed: 2547691 pmcid: 1203724 doi: 10.1093/genetics/122.3.491
Vallet, S.-U. et al. Loss of bacterial cell pole stabilization in Caulobacter crescentus sensitizes to outer membrane stress and peptidoglycan-directed antibiotics. mBio 11, e00538-20 (2020).
pubmed: 32371598 pmcid: 7403779 doi: 10.1128/mBio.00538-20
Jacobson, A. N., Choudhury, B. P. & Fischbach, M. A. The biosynthesis of lipooligosaccharide from Bacteroides thetaiotaomicron. mBio 9, e02289-17 (2018).
pubmed: 29535205 pmcid: 5850320 doi: 10.1128/mBio.02289-17
Fang, M., Wang, D., Coresh, J. & Selvin, E. Trends in diabetes treatment and control in U.S. adults, 1999–2018. N. Engl. J. Med. 384, 2219–2228 (2021).
pubmed: 34107181 pmcid: 8385648 doi: 10.1056/NEJMsa2032271
Waumans, Y., Baerts, L., Kehoe, K., Lambeir, A.-M. & De Meester, I. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front. Immunol. 6, 387 (2015).
pubmed: 26300881 pmcid: 4528296 doi: 10.3389/fimmu.2015.00387
Rea, D. et al. Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling. Eur. J. Med. Chem. 139, 482–491 (2017).
pubmed: 28826083 doi: 10.1016/j.ejmech.2017.08.024
Nabeno, M. et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem. Biophys. Res. Commun. 434, 191–196 (2013).
pubmed: 23501107 doi: 10.1016/j.bbrc.2013.03.010
Boulton, D. W. Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clin. Pharmacokinet. 56, 11–24 (2017).
pubmed: 27282159 doi: 10.1007/s40262-016-0421-4
Vincent, S. H. et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [
pubmed: 17220239 doi: 10.1124/dmd.106.013136
Nemoto, T. K. & Ohara-Nemoto, Y. Exopeptidases and gingipains in Porphyromonas gingivalis as prerequisites for its amino acid metabolism.Jpn Dent. Sci. Rev. 52, 22–29 (2016).
pubmed: 28408952 doi: 10.1016/j.jdsr.2015.08.002
Oda, H., Saiki, K., Tonosaki, M., Yajima, A. & Konishi, K. Participation of the secreted dipeptidyl and tripeptidyl aminopeptidases in asaccharolytic growth of Porphyromonas gingivalis. J. Periodontal. Res. 44, 362–367 (2009).
pubmed: 19076991 doi: 10.1111/j.1600-0765.2008.01117.x
Olivares, M. et al. The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health. Front. Microbiol. 9, 1900 (2018).
pubmed: 30186247 pmcid: 6113382 doi: 10.3389/fmicb.2018.01900
Thuy-Boun, P. S. et al. Quantitative metaproteomics and activity-based protein profiling of patient fecal microbiome identifies host and microbial serine-type endopeptidase activity associated with ulcerative colitis. Mol. Cell. Proteom. 21, 100197 (2022).
doi: 10.1016/j.mcpro.2022.100197
McFadden, D. W., Rudnicki, M., Nussbaum, M. S., Balasubramaniam, A. & Fischer, J. E. Independent release of peptide YY (PYY) into the circulation and ileal lumen of the awake dog. J. Surg. Res. 46, 380–385 (1989).
pubmed: 2704235 doi: 10.1016/0022-4804(89)90206-0
Liu, C. D., Newton, T. R., Zinner, M. J., Ashley, S. W. & McFadden, D. W. Intraluminal peptide YY induces colonic absorption in vivo. Dis. Colon Rectum 40, 478–482 (1997).
pubmed: 9106700 doi: 10.1007/BF02258396
Stevens, L. J. et al. A higher throughput and physiologically relevant two-compartmental human ex vivo intestinal tissue system for studying gastrointestinal processes. Eur. J. Pharm. Sci. 137, 104989 (2019).
pubmed: 31301485 doi: 10.1016/j.ejps.2019.104989
Zhu, W. et al. Xenosiderophore utilization promotes Bacteroides thetaiotaomicron resilience during colitis. Cell Host Microbe 27, 376–388 (2020).
pubmed: 32075741 pmcid: 7439322 doi: 10.1016/j.chom.2020.01.010
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
pubmed: 34265844 pmcid: 8371605 doi: 10.1038/s41586-021-03819-2
Yu, C.-S., Lin, C.-J. & Hwang, J.-K. Predicting subcellular localization of proteins for Gram-negative bacteria by support vector machines based on n-peptide compositions. Protein Sci. 13, 1402–1406 (2004).
pubmed: 15096640 pmcid: 2286765 doi: 10.1110/ps.03479604
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
pubmed: 19029910 doi: 10.1038/nbt.1511
Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011).
pubmed: 21254760 doi: 10.1021/pr101065j
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).
pubmed: 27348712 doi: 10.1038/nmeth.3901
Colaert, N., Helsens, K., Martens, L., Vandekerckhove, J. & Gevaert, K. Improved visualization of protein consensus sequences by iceLogo. Nat. Methods 6, 786–787 (2009).
pubmed: 19876014 doi: 10.1038/nmeth1109-786
Ursell, T. et al. Rapid, precise quantification of bacterial cellular dimensions across a genomic-scale knockout library. BMC Biol. 15, 17 (2017).
pubmed: 28222723 pmcid: 5320674 doi: 10.1186/s12915-017-0348-8
Stein, F., Kress, M., Reither, S., Piljić, A. & Schultz, C. FluoQ: a tool for rapid analysis of multiparameter fluorescence imaging data applied to oscillatory events. ACS Chem. Biol. 8, 1862–1868 (2013).
pubmed: 23882997 doi: 10.1021/cb4003442

Auteurs

Laura J Keller (LJ)

Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.

Taylor H Nguyen (TH)

Department of Bioengineering, Stanford University, Stanford, CA, USA.

Lawrence J Liu (LJ)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.

Brianna M Hurysz (BM)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.

Markus Lakemeyer (M)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Institute of Organic Chemistry and Macromolecular Chemistry, Friedrich-Schiller-University, Jena, Germany.

Matteo Guerra (M)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Biochemical and Cellular Pharmacology, Genentech, San Francisco, CA, USA.

Danielle J Gelsinger (DJ)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.

Rachael Chanin (R)

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Divisions of Hematology and Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA, USA.

Nhi Ngo (N)

Lundbeck La Jolla Research Center, Inc., San Diego, CA, USA.

Kenneth M Lum (KM)

Lundbeck La Jolla Research Center, Inc., San Diego, CA, USA.

Franco Faucher (F)

Department of Chemistry, Stanford University, Stanford, CA, USA.

Phillip Ipock (P)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Micah J Niphakis (MJ)

Lundbeck La Jolla Research Center, Inc., San Diego, CA, USA.

Ami S Bhatt (AS)

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Divisions of Hematology and Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA, USA.

Anthony J O'Donoghue (AJ)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.

Kerwyn Casey Huang (KC)

Department of Bioengineering, Stanford University, Stanford, CA, USA.
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Chan Zuckerberg Biohub, San Francisco, CA, USA.

Matthew Bogyo (M)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. mbogyo@stanford.edu.
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. mbogyo@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH